A Phase 3 Open-label Multi-Center, Two-Part Single-arm Study to Evaluate the Acute Vasodilation Response of Inhaled Nitric Oxide as a Predictor of Successful Wean From Parental Prostacyclins in Subjects With Pulmonary Arterial Hypertension
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms EAGLE
- Sponsors Vero Biotech
- 04 Sep 2015 Status changed from recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 30 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
- 13 May 2015 New trial record